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Severe acute respiratory syndrome (SARS) is an infectious and highly contagious 
disease that is caused by SARS-associated coronavirus (SARS-CoV). Viral entry is a 
key target step for therapies because it can prevent the propagation of virus at early 
stages of the disease.  We used a cell-based assay to identify inhibitors of SARS-CoV 
entry. We prepared a pseudotyped virus in which the core is from HIV and envelop is 
from the SARS-CoV (HIV-luc/SARS env). This pseudotyped virus was used to infect, 
293T cells expressing the receptor for SARS-CoV, Aangiotensin-converting enzyme-2 
(ACE2). 
Using this assay we screened a chemical library of more than 2000 compounds and 
identified three compounds that specifically inhibit entry of the HIV-luc/SARS env. 
These compounds did not inhibit another pseudotyped virus which had same core from 
HIV but envelop was from Vesicular Stomatitis Virus. The compounds had strong 
potencies (EC50s were 2.9, 4.8 and 5.8 µM) and low cytotoxicities (high CC50s) resulting 
in promising Selectivity Indices (CC50/EC50 were >175, >65, and >86, respectively). 
Importantly, the compounds were found to have excellent antiviral activities, blocking 
SARS-CoV replication at low nM concentrations. Only one of the compounds was a 
moderate inhibitor of cathepsin L, a cellular protease whose activity is required to 
process the SARS-CoV env glycoprotein (Spike) and allow viral entry. Moreover, none 
of the compounds affects the cleavage activity of furin, another host protease, which 
may also be involved in SARS-CoV entry. Using a flow cytometry binding assay, we 
found that all three compounds decrease binding of the SARS-CoV Spike receptor 
binding domain to ACE2 receptor expressed on the surface of 293Tcells.  
Hence, we have discovered three promising compounds as the first small molecule 
inhibitors that can block receptor-dependent entry of SARS-CoV.  
 
 
